Natera (NTRA) stock rose 7.67% after Japan approved Signatera for colorectal cancer MRD testing, marking the country’s first authorized test of its kind. The post Natera (NTRA) Stock Soars 7% Following Japanese Regulatory Milestone for Signatera appeared first on…
Source link
Be the first to comment